Filtered By:
Education: Study
Procedure: Heart Valve Surgery

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 1859 results found since Jan 2013.

Mitral valve replacement for mitral stenosis: A 15-year single center experience
Conclusion MMV replacement in mitral stenosis patients is associated with a lower reoperation rate, but there was no difference in survival compared with BMV replacement.
Source: Journal of the Saudi Heart Association - March 18, 2016 Category: Cardiology Source Type: research

Edwards Lifesciences hits all-time high on Sapien 3 study
Shares in Edwards Lifesciences (NYSE:EW) hit an all-time high yesterday after the company reported strong 1-year data for its Sapien 3 replacement heart valve over the weekend. Results from the Partner II trial from 1,077 intermediate-risk patients showed that the Sapien 3 beat surgical valve replacement across a variety of safety endpoints, Irvine, Calif.-based Edwards said at the American College of Cardiology’s annual meeting April 3. The combined all-cause death & disabling stroke rate was 8.4% for TAVR with Sapien 3 and 16.6% for the surgery arm, according to the study, which was also published in The Lan...
Source: Mass Device - April 5, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Replacement Heart Valves Wall Street Beat American College of Cardiology Conference (ACC) Edwards Lifesciences Source Type: news

MassDevice.com +5 | The top 5 medtech stories for April 5, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Medtronic’s Resolute Integrity tops Abbott’s Xience | ACC 2016 roundup Results from the Propel all-comers trial comparing Medtronic‘s Resolute Integrity drug-eluting stent showed it to be superior to the Xience stent made...
Source: Mass Device - April 5, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Comparison of the Performance of a Sutureless Bioprosthesis With Two Pericardial Stented Valves on Small Annuli: An In  Vitro Study
Conclusions All of the valves tested provided good fluid dynamic performances. The sutureless bioprosthesis provided the best performance with the least hindrance to flow behavior. From the hydrodynamic perspective, the sutureless prosthesis may present an advance in the evolution of bioprostheses, ensuring low gradients and potential for low incidence of patient-prosthesis mismatch even in small annuli.
Source: The Annals of Thoracic Surgery - August 17, 2016 Category: Cardiovascular & Thoracic Surgery Source Type: research

Comparison of the Performance of a Sutureless Bioprosthesis With Two Pericardial Stented Valves on Small Annuli: An In  Vitro Study.
CONCLUSIONS: All of the valves tested provided good fluid dynamic performances. The sutureless bioprosthesis provided the best performance with the least hindrance to flow behavior. From the hydrodynamic perspective, the sutureless prosthesis may present an advance in the evolution of bioprostheses, ensuring low gradients and potential for low incidence of patient-prosthesis mismatch even in small annuli. PMID: 27544288 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - August 16, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Tasca G, Vismara R, Mangini A, Romagnoni C, Contino M, Redaelli A, Fiore GB, Antona C Tags: Ann Thorac Surg Source Type: research

Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Conclusions Use of EP seems to be associated with reductions in imaging markers of cerebral infarction and early clinical neurological effectiveness in patients undergoing TAVR.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - October 23, 2016 Category: Cardiology Authors: Giustino, G., Mehran, R., Veltkamp, R., Faggioni, M., Baber, U., Dangas, G. D. Tags: Structural Source Type: research

Transcatheter Aortic Valve Replacement: The New Standard in Patients With Previous Coronary Bypass Grafting?
Conclusions Since its introduction in 2007, TAVR has been increasingly used in Germany in patients with previous CABG, and in-hospital outcome data support the trend away from redo surgery.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - October 23, 2016 Category: Cardiology Authors: Reinöhl, J., Kaier, K., Reinecke, H., Frankenstein, L., Zirlik, A., Zehender, M., von zur Mühlen, C., Bode, C., Stachon, P. Tags: Structural Source Type: research

Transcatheter Aortic Valve Implantation for Treatment of Aortic Valve Stenosis: A Health Technology Assessment.
CONCLUSIONS: Moderate quality evidence showed that TAVI and SAVR had similar mortality rates in patients who were eligible for surgery. Information about quality of life showed similar results for TAVI and SAVR in the first year, but was based on low quality evidence. Moderate quality evidence also showed that TAVI was associated with higher rates of adverse events than SAVR. In patients who were not suitable candidates for surgery, moderate quality evidence showed that TAVI improved survival compared with balloon aortic valvuloplasty. When TAVI was compared with SAVR, the incremental cost-effectiveness ratio was $51,988 p...
Source: Ontario Health Technology Assessment Series - December 21, 2016 Category: Journals (General) Tags: Ont Health Technol Assess Ser Source Type: research

10-year results of On-X bileaflet mechanical heart valve in the aortic position: low target INR regimen in Japanese
ConclusionsAVR using On-X valve with low target INR regimen and low-dose aspirin resulted in a significantly low risk of bleeding.
Source: General Thoracic and Cardiovascular Surgery - April 19, 2017 Category: Cardiovascular & Thoracic Surgery Source Type: research

Impact of pre ‐existing or new‐onset atrial fibrillation on 30‐day clinical outcomes following Transcatheter Aortic Valve Replacement: Results From The BRAVO 3 Randomized Trial
Conclusions: Prior or new‐onset AF within 30 days of transfemoral TAVR is noted in more than one‐third of patients. Despite greater baseline comorbidities than non‐AF patients, AF was not associated with greater risk of adjusted 30‐day outcomes. In the BRAVO 3 trial, early outcomes were similar regardless of anticoagulant strategy in each group. This article is protected by copyright. All rights reserved.
Source: Catheterization and Cardiovascular Interventions - May 1, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Christian Hengstenberg, Jaya Chandrasekhar, Samantha Sartori, Thierry Lefevre, Ghada Mikhail, Nicolas Meneveau, Christophe Tron, Raban Jeger, Christian Kupatt, Birgit Vogel, Serdar Farhan, Sabato Sorrentino, Madhav Sharma, Clayton Snyder, Oliver Husser, P Tags: VSD ‐ Valvular and Structural Heart Diseases Source Type: research

Dual Versus Single Antiplatelet Regimen With or Without Anticoagulation in Transcatheter Aortic Valve Replacement: Indirect Comparison and Meta-analysis
Conclusions The present meta-analysis supports the use of DAPT after TAVR, reducing mortality and offering slight benefits in stroke, with no increase in major bleedings compared with MAPT. The strategy of aspirin + oral anticoagulation did not provide significant benefits compared with MAPT or DAPT.
Source: Revista Espanola de Cardiologia - July 20, 2017 Category: Cardiology Source Type: research

Lower Transaortic Flow Rate Is Associated With Increased Mortality in Aortic Valve Stenosis
Conclusions In patients with AS without known cardiovascular disease or diabetes, low transaortic FR was independently associated with higher rates of cardiovascular and all-cause mortality. (An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart) (MK-0653A-043 AM4); NCT00092677)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - August 7, 2017 Category: Radiology Authors: Saeed, S., Senior, R., Chahal, N. S., Lonnebakken, M. T., Chambers, J. B., Bahlmann, E., Gerdts, E. Tags: Original Research Source Type: research

Optimized Screening of Coronary Artery Disease With Invasive Coronary Angiography and Ad Hoc Percutaneous Coronary Intervention During Transcatheter Aortic Valve Replacement Structural Heart Disease
Conclusions— In patients undergoing TAVR, screening of CAD with invasive coronary angiography and ad hoc PCI during TAVR is feasible and was not associated with increased periprocedural risks. PCI followed by TAVR in the same session had similar outcomes than TAVR in which PCI was not performed.
Source: Circulation: Cardiovascular Interventions - August 2, 2017 Category: Cardiology Authors: Barbanti, M., Todaro, D., Costa, G., Pilato, G., Picci, A., Gulino, S., Capranzano, P., La Spina, K., Di Simone, E., DArrigo, P., Deste, W., Indelicato, A., Cannata, S., Giannazzo, D., Imme, S., Tamburino, C., Patane, M., Buccheri, S., Capodanno, D., Sgro Tags: Diagnostic Testing, Aortic Valve Replacement/Transcatheter Aortic Valve Implantation Structural Heart Disease Source Type: research

Claret Medical raises $21m to support Sentinel system
Claret Medical has raised $21.2 million in a new round of equity financing, according to an SEC filing posted last week. In a press release posted today, the company said that it raised $14.5 million in a Series C round led by Lightstone Ventures and joined by Easton Capital, HealthCor Partners, Incept and Sante Ventures. Proceeds are slated to support market access program, next-gen R&D and expanding commercialization to support its Sentinel cerebral protection system. The Sentinel embolic protection device is designed to trap blood clots and prevent stroke during heart valve replacement procedures, which Claret Medic...
Source: Mass Device - October 23, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Claret Medical Inc. Source Type: news

TCT 2017: Medtronic touts results from 6-month Evolut Pro study
Medtronic (NYSE:MDT) today released six-month data from a study of its Evolut Pro transcatheter aortic valve replacement platform, touting low rates of paravalvular leaks and low rates of all-cause mortality and disabling stroke. Data came from 60 patients in the trial who received the Evolut Pro valve, and follow previously released 30-day outcomes. Results at six-months indicated trace or no paravalvular leaks in 88% of patients, with low rates of all-cause mortality and disabling stroke. No instances of coronary obstruction or valve thrombosis were reported and the permanent pacemaker implantation rate was 11.7%, Medt...
Source: Mass Device - November 2, 2017 Category: Medical Devices Authors: Fink Densford Tags: Catheters Clinical Trials Replacement Heart Valves Medtronic Source Type: news